DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
9.13
-0.04 (-0.44%)
Apr 29, 2025, 4:00 PM EDT - Market closed
DBV Technologies Employees
As of December 31, 2024, DBV Technologies had 110 total employees, including 109 full-time and 1 part-time employees. The number of employees increased by 5 or 4.76% compared to the previous year.
Employees
110
Change (1Y)
5
Growth (1Y)
4.76%
Revenue / Employee
$37,736
Profits / Employee
-$1,035,618
Market Cap
238.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
DBVT News
- 18 days ago - DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - GlobeNewsWire
- 4 weeks ago - DBV Technologies ADRs Rise After Up to $306.9M in New Financing - Market Watch
- 4 weeks ago - DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved - GlobeNewsWire
- 5 weeks ago - DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - GlobeNewsWire
- 3 months ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 4 months ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 4 months ago - DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - GlobeNewsWire